European Medicines Agency grants AUTO1 (CAR-T cell therapy) Priority Medicines (PRIME) designation for the treatment of adults with acute lymphocytic leukaemia

AUTO1 is a CD19 CAR T cell investigational therapy, designed to have a fast target binding off-rate to minimise excessive activation of the programmed T cells. It is currently being evaluated in a Phase I trial (ALLCAR) and has recently progressed to the Phase Ib/II FELIX study

Biospace Inc.